ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
An Injectable, Self-Expanding Hemostatic Foam for Field-Compatible Postpartum Hemorrhage Management.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Postpartum hemorrhage (PPH) remains the leading cause of maternal mortality worldwide and a major contributor to global morbidity. Although several interventions exist in high-income countries, current solutions often suffer from poor field-compatibility, limited efficacy, complex application, insufficient hemostatic support, and difficult removal. Here, a hemostatic foam designed for field compatibility and made from stable precursors, together with an easy-to-use delivery device for treating life-threatening PPH is introduced. The device enables rapid, user-friendly generation and intrauterine application of a hydrogel foam, which controls bleeding through both coagulation support and tamponade pressure before safely degrading. The expanding foam achieves the target pressure range of standard intrauterine tamponade (67-92 mmHg), confirmed across in vitro, ex vivo, and in vivo models. Induced degradation produces 76 ± 8% mass loss within 6 h, with storage modulus dropping from 2.98 ± 0.08 kPa after fabrication to 1.60 ± 0.25 kPa after partial degradation. Incorporation and controlled release of tranexamic acid and cefuroxime show versatility in topical drug delivery. Beyond extensive ex vivo testing, rapid, controlled deployment in vivo in a swine model is demonstrated. By integrating mechanical and chemical mechanisms, this injectable foam provides effective bleeding control, with a design well suited to low-resource settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.